Brought to you by 
NeoPharm grants Hope Bioscience rights to preclinical cancer therapy
29 Oct 2021
Executive Summary
NeoPharm Co. Ltd. granted Hope Biosciences exclusive global rights to develop and sell its MERTK/AXL/pan-C-MET tyrosine kinase inhibitor, which Hope has named HOPE777.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NeoPharm grants Hope Bioscience rights to preclinical cancer therapy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice